文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

初程立体定向放射外科后高负荷颅内进展的临床相关因素:多中心脑转移队列

Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort.
PubMed 文献 · Adv Radiat Oncol · 2025-07-11

该多中心回顾性队列纳入2015年1月至2020年12月完成初程SRS的1383例患者,分析初程SRS时临床参数与高负荷颅内进展(ICP5:≥5个新发脑转移;ICP11:≥11个)的关系。结果显示高负荷ICP与总生存下降及神经症状增加相关;寡转移、SRS后免疫治疗、初程SRS时单个脑转移为高负荷ICP的负性预测因素。

要点

  • 高负荷颅内进展(≥5或≥11个新发脑转移)与总生存下降及神经症状增加相关。
  • 初程SRS时寡转移、SRS后免疫治疗、初程SRS时单个脑转移与高负荷ICP风险降低相关。
  • 初程SRS前未接受免疫治疗与ICP11风险升高相关。

核心结论

  • 高负荷颅内进展与总生存下降及神经功能恶化相关。
  • 寡转移、SRS后免疫治疗、初程SRS时单个脑转移与高负荷ICP风险降低相关。
  • 初程SRS前未接受免疫治疗与ICP11风险升高相关。

研究设计与样本

  • 两中心回顾性队列,纳入2015年1月至2020年12月完成初程SRS的全部患者,共1383例。
  • 采用Kaplan-Meier法估计总生存和无ICP生存,Cox模型评估临床参数与无ICP5、无ICP11生存的关联。

主要发现

  • 555例(40.1%)患者出现SRS后ICP,其中72.6%为1至4个进展脑转移,11.5%为5至10个,15.9%为≥11个新发脑转移。
  • 上述三组12个月总生存分别为56.8%(95%CI:52.1%-61.9%)、46.0%(95%CI:35.1%-60.1%)、38.7%(95%CI:29.4%-50.9%),P<.001。
  • ICP时神经症状发生率在三组分别为21.1%、28.1%、50.0%,P<.001。
  • 初程SRS时寡转移与ICP5风险降低相关(HR 0.68,95%CI:0.47-0.99),与ICP11风险降低相关(HR 0.59,95%CI:0.36-0.97)。
  • SRS后免疫治疗与ICP5风险降低相关(HR 0.60,95%CI:0.402-0.906),与ICP11风险降低相关(HR 0.57,95%CI:0.332-0.988)。

关键数值与推荐

  • 高负荷ICP定义为≥5个脑转移(ICP5)或≥11个脑转移(ICP11)。
  • 初程SRS前未接受免疫治疗与ICP11风险升高相关(HR 1.74,95%CI:1.03-2.97)。
  • 初程SRS时单个脑转移对比2个脑转移:ICP5的HR为0.51(95%CI:0.31-0.82),ICP11的HR为0.45(95%CI:0.24-0.84)。

临床怎么用

  • 对具有高负荷ICP风险因素的患者,可考虑 upfront 全脑放疗。
  • 对该人群可考虑开展SRS后短间隔监测的前瞻性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Following initial stereotactic radiosurgery (SRS), risk factors for high-burden intracranial progression (ICP) necessitating whole brain radiation remain poorly characterized. We hypothesize that specific clinical parameters at initial SRS are associated with high-burden ICP-defined as either ≥5 brain metastases (BMs) (ICP5) or ≥11 BMs (ICP11). MATERIALS AND METHODS: Across 2 institutions, we retrospectively identified all patients completing an initial SRS course from January 2015 to December 2020. ICP was defined as any radiographic concern for distant and/or in-field progression. Overall survival (OS) and freedom from ICP were estimated via the Kaplan-Meier method. Cox models assessed the association between clinical parameters and freedom from ICP5 and ICP11. RESULTS: We identified 1383 patients completing SRS. Post-SRS ICP was identified for 555 (40.1%) patients: 72.6% had 1 to 4 progressive BMs, 11.5% had 5 to 10 BMs, and 15.9% had ≥11 new BMs. Among these groups, 12-month OS was 56.8% (95% CI: 52.1%-61.9%), 46.0% (95% CI: 35.1%-60.1%), and 38.7% (95% CI: 29.4%-50.9%), respectively (P < .001). Neurologic symptoms at ICP were observed in 21.1%, 28.1%, and 50.0% of cases, respectively (P < .001). Oligometastatic disease at the time of SRS [ICP5: hazard ratio (HR) 0.68, 95% CI: 0.47-0.99; ICP11: 0.59; 95% CI: 0.36-0.97], no pre-SRS immunotherapy (ICP11: HR 1.74, 95% CI: 1.03-2.97), receipt of post-SRS immunotherapy (ICP5: HR 0.60, 95% CI: 0.402-0.906; ICP11: HR 0.57, 95% CI: 0.332-0.988), and a single BM at initial SRS (1 vs 2 BM, ICP 5: HR 0.51, 95% CI: 0.31-0.82; ICP11: HR 0.45, 95% CI: 0.24-0.84) were negative predictive factors of high-burden ICP. CONCLUSIONS: High-burden ICP was associated with decreased OS and neurologic decline. Patients who had oligometastatic disease, who received post-SRS immunotherapy, who did not receive pre-SRS immunotherapy, and who had a single BM had improved freedom from high-burden ICP. These findings may justify consideration of upfront whole brain radiation for those at risk for high-burden ICP and prospective analysis of short-interval post-SRS surveillance in this population.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang CC, Carpenter DJ, Leng J, et al. Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort. Adv Radiat Oncol. 2025. PMID: 40800218. doi:10.1016/j.adro.2025.101859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。